<DOC>
	<DOC>NCT00338897</DOC>
	<brief_summary>The primary objective is to: - demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery. The secondary objectives are to: - evaluate the safety of SR123781A in the prevention of VTE after elective total hip replacement surgery; and - to assess the SR123781A pharmacokinetic profile in patients undergoing elective total hip replacement surgery.</brief_summary>
	<brief_title>Dose Ranging Study in Elective Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>Patients scheduled to undergo elective total hip replacement surgery or a revision of at least one component of a total hip replacement performed &gt; 6 months prior to study entry Pregnant or nursing women, or women of childbearing potential who are not using an effective contraceptive method and who do not have a negative pregnancy test performed immediately before randomization Known progressive malignant disease Ischemic stroke in the last 3 months Myocardial infarction (MI) in the last 3 months Any major orthopedic surgery in the 3 months prior to study start Clinical signs or symptoms of DVT or PE within the last 12 months or symptoms of post phlebitic syndrome (these conditions may confound DVT/PE assessments) Treatment with other antithrombotic agents within 7 days prior to surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Prevention</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Replacement</keyword>
	<keyword>Hip</keyword>
	<keyword>orthopedic surgery</keyword>
</DOC>